Objective: To compare the perioperative outcomes of single extrahepatic portosystemic shunt occlusion by complete and partial silk ligation and ameroid constrictor placement in dogs.
Design: A retrospective analysis of 30 dogs with single congenital extrahepatic shunts.
Procedure: Records between 1990 and 2000 were reviewed. Patient age, breed, weight, presenting clinical signs, clinical pathology results, diagnostic imaging results, the surgery procedure performed, implant used, time taken, intra operative complications and perioperative complications were recorded. Mortality rates were calculated.
Results: Twenty dogs had a silk ligation procedure, 10 partially occluded and 10 completely. Ten dogs had an ameroid constrictor placement procedure. Ameroid constrictor surgery was significantly shorter in duration than silk ligation. Time for silk ligation was 91.8 +/- 35.2 minutes (median 90.0); time for ameroid constrictor placement was 71.5 +/- 12.0 (median 72.5, P = 0.049). A reduction in intraoperative complications was also noted in the ameroid constrictor surgery group.
Conclusion: The ameroid constrictor offered a surgical occlusion procedure of single extrahepatic portosystemic shunts in dogs that was clinically as effective as silk ligation in the perioperative period, with a significantly shorter surgery time.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1751-0813.2003.tb12532.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A mouse model of deep vein thrombosis by inferior vena cava hypoperfusion using ameroid constrictors.
Sci Rep
January 2025
Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Kanagawa, Japan.
Traditional mouse models for deep vein thrombosis (DVT), frequently utilized in research focused on cancer-associated thrombosis (CAT), reliably induce thrombus formation by obstructing blood flow (BF) in the inferior vena cava (IVC), which does not occur in humans. Therefore, to develop a new DVT model for CAT studies, we implanted an ameroid constrictor (AC), a hygroscopic casein C-shape device, around the IVC and aorta of immunocompromised mice. We evaluated the thrombus 3 and 8 days post-AC implantation and compared it with the traditional model 2 days post-vena cava ligation.
View Article and Find Full Text PDFSemaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease.
Arterioscler Thromb Vasc Biol
February 2025
Department of Cardiothoracic Surgery, Brown University, Providence, RI.
Background: Coronary artery disease is the leading cause of death worldwide. It imposes an enormous symptomatic burden on patients, leaving many with residual disease despite optimal procedural therapy and up to one-thirds with debilitating angina amenable neither to procedures, nor to current pharmacological options. Semaglutide (SEM), a GLP-1 (glucagon-like peptide 1) agonist originally approved for management of diabetes, has garnered substantial attention for its capacity to attenuate cardiovascular risk.
View Article and Find Full Text PDFSodium-Glucose Cotransporter-2 Inhibition Normalizes Metabolic Derangements in the Ischemic Myocardium.
J Surg Res
November 2024
Division of Cardiothoracic Surgery, Department of Surgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island. Electronic address:
Introduction: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have shown efficacy in the context of heart failure but have not been well-studied in ischemic heart disease. We employed a large animal model of chronic coronary artery disease and metabolic syndrome (MS) to investigate the hemodynamic and metabolic consequences of SGLT2i administration.
Methods: Thirty-eight Yorkshire swine were divided into two groups, with half (n = 21) receiving a high fat diet to induce MS, and the other half fed a standard diet (n = 17).
Objective: Coronary artery disease (CAD) is the leading cause of death worldwide. It imposes an enormous symptomatic burden on patients, leaving many with residual disease despite optimal procedural therapy, and up to 1/3 with debilitating angina amenable neither to procedures, nor to current pharmacologic options. Semaglutide, a glucagon-like peptide 1 agonist originally approved for management of diabetes, has garnered substantial attention for its capacity to attenuate cardiovascular risk.
View Article and Find Full Text PDFResveratrol Mitigates Cognitive Impairments and Cholinergic Cell Loss in the Medial Septum in a Mouse Model of Gradual Cerebral Hypoperfusion.
Antioxidants (Basel)
August 2024
Peritz Scheinberg Cerebral Vascular Disease Research Laboratories, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA.
Vascular cognitive impairment and dementia (VCID) is the second leading cause of dementia. There is currently no effective treatment for VCID. Resveratrol (RSV) is considered an antioxidant; however, our group has observed pleiotropic effects in stroke paradigms, suggesting more effects may contribute to mechanistic changes beyond antioxidative properties.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!